AzTrials
AzTrials

Central Nervous System DiseaseNCT07471984

Validation on Clinical Adaptability of the Foundation Model Specific to Neuroimaging Diagnosis

An observational study of Central Nervous System Disease and MRI, run by Yaou Liu at 1 site in China.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

This clinic trial aims to investigate whether artificial intelligence (AI) diagnostic tools at neurological diseases diagnosis on brain CT/MRI can improve the work efficiency of specialized neuroimaging physicians, with a specific focus on its clinical value in distinguishing normal from abnormal findings, critical… Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
Central Nervous System Disease, MRI, CT
What is being tested?
Foundation Model Specific to Neurological Diagnosis
How many people
50,000 participants
Where
1 siteChina
Study dates
1 May 2025to 1 Dec 2030
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: All patient exams are suspected of harboring brain tumors or the other neurological diseases, with or without neurological symptoms, and without a history of prior brain surgery or inpatient/outpatient medical records. Patients underwent brain CT and MRI, and were primarily examined at Beijing Tiantan hospital, between 2012-2026.

Who may be able to join

  • For MRI: patients suspected of harboring ischemic, hemorrhagic, brain tumors, degenerative brain disease, or traumatic brain injury at initiating or other institution, who subsequently underwent brain MRI;
  • For CT: patients with or without neurological symptoms, suspected of harboring ischemic, hemorrhagic, space-occupying, degenerative brain disease, or traumatic brain injury, who subsequently underwent brain CT.

Who cannot join

  • Patients who opted-out or did not give permission to reuse clinical data.
  • Patients with a history of prior brain surgery.
  • Patients whose brain CT or MRI exhibit severe artifacts (e.g. heavy warping due to air, metal artifacts, heavy motion artifacts), thereby impeding the usage of the data.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

China1 site
  • Beijing Tiantan Hospital

    Beijing

Other trials in China

About this study

Official title: Validation on Clinical Adaptability of the Foundation Model Specific to Neuroimaging Diagniosis

This clinic trial aims to investigate whether artificial intelligence (AI) diagnostic tools at neurological diseases diagnosis on brain CT/MRI can improve the work efficiency of specialized neuroimaging physicians, with a specific focus on its clinical value in distinguishing normal from abnormal findings, critical value identification, and neurological disease classification. Using pathological and/or discharge diagnoses of neurological diseases as the gold standard, an AI model will be trained on over 10,000 CT/MRI cases to achieve diagnostic performance comparable to that of neurological radiologists before being transformed and putted to use. Furthermore, clinical trials will be conducted in sub-studies (abnormal cases identification, critical value assessment, and neurological disease classification) to validate the clinical utility of AI and human-AI collaboration in the precise diagnosis of neurological disorders. The expected outcomes include reducing missed and misdiagnosis rates, enabling rapid screening of critical conditions, and achieving precise imaging-based diagnosis by using AI tools.

Read the detailed description

Neurological disorders pose a severe threat to human health and create a substantial socio-economic burden. Imaging examinations, including CT and MRI, play an indispensable role in disease screening, noninvasive diagnosis, and guiding treatment decision. Artificial intelligence (AI) tools have shown promising clinical application prospects in releasing the productivity of radiologists and shortening patients' waiting time, particularly in critical care settings and medically underserved regions. Although AI tools trained on foundation model are supposed to have reliable generalization and can adapt to complex clinical scenarios, current AI systems often lack robust validation in real-world clinical practice.

In the face of growing demands for precision medicine and the deluge of medical imaging data, clinical trials are essential for validating the diagnostic efficacy of AI-assisted systems and their applicability in broader clinical settings. Based on a multidisciplinary team (integrating expertise in AI, radiology, emergency, neurology, and pathology) and prior research experience, this study has designed a comprehensive and robust research protocol to ensure the reliability of the trial, ultimately facilitating clinical translation.

This study hypothesizes that the working performance of the radiologists collaborating with the neuroimaging foundation model for brain CT and MRI is non-inferior to those who work standalone. For the secondary end-points, we investigate the performance of AI-radiologist collaboration of AI tools in real clinical environment. The clinic trial contains three sub-studies:

  1. Identifying abnormal cases Brain scanning, including normal and all neurological disease coverage on both CT and MRI, were randomly given to two groups of radiologists to classify into normal or abnormal cases with or without the predicted label from the AI-assisted system. Comparing the sensitivity, specificity, and efficiency of radiologists collaborating with AI or working standalone.
  2. Study for critical value identification The study involved a prospective, randomized selection of emergency CT data from a 1-to-3-day window. The performance of three paradigms-human-only, AI-only, and human+AI-was separately evaluated based on diagnostic accuracy, time efficiency, and the critical metric of lead time in identifying urgent findings when AI was integrated compared to that of human-only.
  3. Disease classification experiment A prospectively selected dataset from a specific time period, comprising both CT and MRI examinations, was utilized. The experiment compares the performance of three diagnostic approaches, including human-only interpretation, AI-only analysis and human-AI collaborative interpretation. Part I, task completion time, diagnostic accuracy, and diagnostic recall rate (for cases with multiple labels) were calculated and compared across the three methods as follows: (1)Radiologists independently select and utilize provided disease templates for report generation, then extract diagnosis labels from the reports; (2) Radiologists generate reports while browsing images with the aid of AI-generated category labels and AI-assigned report templates based on the "midnights" major classification system; (3)AI automatically generates the complete report and classification labels. Part II, the original reporting radiologists were recalled to re-interpret the studies, and this re-evaluation was performed with the assistance of AI-generated labels and matched templates. Part Ⅲ, leveraging the classification capabilities of a large language model/foundation model, the system was evaluated on multiple large-sample external test sets to measure accuracy and processing time. Additionally, a randomized subset of cases from various categories was selected for assessment by neuroradiologists to calculate the rate of missed diagnoses and misdiagnoses.
Being tested
Foundation Model Specific to Neurological Diagnosis
Medical subject headings
Central Nervous System Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Foundation Model Specific to Neurological DiagnosisDiagnostic test

    Validating the diagnostic efficacy of AI-assisted systems and their applicability in clinical settings based on CT/MRI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The diagnostic performance of human-AI collaborative approach in identifying abnormal case is not inferior to that of human-only and AI-only

    AI models and over 50 radiologists at neurological diseases on brain CT/MRI to assess the working performance of neuroimaging AI diagnostic tools for differentiating normal and abnormal examinations

    Measured: 6 months

  2. The diagnostic performance of human-AI collaborative approach in critical value judgment is not inferior to that of human-only and AI-only

    To improve the turnaround time and quality of urgent diagnostic reports on brain CT/MRI, the performance of three paradigms-human-only, AI-only, and human+AI-was evaluated based on diagnostic accuracy, time efficiency, and the critical metric of lead time in identifying urgent findings when AI was integrated compared to that of human-only.

    Measured: 6 months

Secondary outcomes (3)
  1. The diagnostic performance of human-AI collaborative approach in disease classification is not inferior to that of human-only and AI-only

    The interpretation for disease classification experiment including such steps: (1)Radiologists independently select and utilize provided disease templates for report generation, then extract diagnosis labels from the reports; (2) Radiologists generate reports while browsing images with the aid of AI-generated category labels (91 classes) and AI-assigned report templates based on the "midnights" major classification system; (3) AI automatically generates the complete report and classification labels.

    Measured: 6 months

  2. The diagnostic performance of human-AI collaborative approach in disease classification is superior to that of human-only

    The original reporting physicians are recalled to re-interpret the studies, and this re-evaluation is performed with the assistance of AI-generated labels and matched templates.

    Measured: 6 months

  3. The diagnostic performance of current model in disease classification on brain CT and MRI is superior to comparable models on a large-scale external dataset

    This standalone test evaluates the classification capabilities of current model and comparable models on multiple large scale external data, with main measurement indicators of accuracy and processing time. A randomized subset will be selected for assessment by neuroradiologists to calculate the rate of missed diagnoses and misdiagnoses.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2026
  2. Study start1 May 2025
  3. Primary completion1 Oct 2025
  4. Study completion1 Dec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
50,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07471984
Sponsor's protocol ID
2025-A10
Other IDs
2025-A09
Status last verified
Sep 2025
First submitted
5 Mar 2026
Last updated
13 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Central Nervous System Disease and MRI, run by Yaou Liu at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 13 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The diagnostic performance of human-AI collaborative approach in identifying abnormal case is not inferior to that of human-only and AI-only (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in